This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Men's Health  • Men's Sexual Function  • Neurology  • Neuro-ophthalmology  • Ophthalmological Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2005;123:400-401.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Tadalafil, a selective cyclic guanosine monophosphate (cGMP)–specific phosphodiesterase type 5 (PDE5) inhibitor, enhances penile erectile function in men. Nitric oxide along with cGMP promotes blood flow to and dilation of smooth muscle in the corpus cavernosum of the penis. Phosphodiesterase type 5 inhibitors prevent degradation of cGMP to potentiate erectile function. Tadalafil (Cialis; Lily ICOS LLC, Indianapolis, Ind) is one of the PDE5 inhibitors approved for erectile dysfunction, which also include sildenafil citrate (Viagra; Pfizer, Inc, New York, NY) and vardenafil hydrochloride (Levitra; Bayer AG, Leverkusen, Germany, and GlaxoSmithKline, Uxbridge, England).

The package insert for tadalafil describes adverse ophthalmic reactions that include blurred vision, changes in color vision, conjunctivitis, eye pain, tearing, and swelling of the eyelids. Some reports suggest that sildenafil use may be associated with nonarteritic anterior ischemic optic neuropathy (NAION).^1-3 We describe a patient who took tadalafil 5 times in 1 month. He developed transient inferior visual . . . [Full Text of this Article]

Report of a Case


Comment

AUTHOR INFORMATION
Kathryn Bollinger, MD, PhD; Michael S. Lee, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Non-arteritic anterior ischaemic optic neuropathy and phosphodiesterase-5 inhibitors
Hayreh
Br J Ophthalmol 2008;92:1577-1580.
FULL TEXT  

Hypothesis: A Venous Etiology for Nonarteritic Anterior Ischemic Optic Neuropathy
Levin and Danesh-Meyer
Arch Ophthalmol 2008;126:1582-1585.
FULL TEXT  

Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
Danesh-Meyer and Levin
Br J Ophthalmol 2007;91:1551-1555.
ABSTRACT | FULL TEXT  

Can erectile dysfunction drug use lead to ischaemic optic neuropathy?
Pomeranz
Br J Ophthalmol 2006;90:127-128.
FULL TEXT  

BJO at a glance
Hoyt
Br J Ophthalmol 2006;90:127-127.
FULL TEXT